TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.

Loading...
Thumbnail Image

Embargo End Date

Authors

Thomson, DJ
Cruickshank, C
Baines, H
Banner, R
Beasley, M
Betts, G
Bulbeck, H
Charlwood, F
Christian, J
Clarke, M
Donnelly, O
Foran, B
Gillies, C
Griffin, C
Homer, JJ
Langendijk, JA
Lee, LW
Lester, J
Lowe, M
McPartlin, A
Miles, E
Nutting, C
Palaniappan, N
Prestwich, R
Price, JM
Roberts, C
Roe, J
Shanmugasundaram, R
Simões, R
Thompson, A
West, C
Wilson, L
Wolstenholme, J
Hall, E

Document Type

Journal Article

Date

2022-11-01

Date Accepted

2022-11-18

Abstract

•There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).•TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.•Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.•There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.

Citation

Clinical and Translational Radiation Oncology, 2022,

Source Title

Clinical and Translational Radiation Oncology

Publisher

ELSEVIER IRELAND LTD

ISSN

2405-6308

eISSN

Collections

Research Team

Clin Trials & Stats Unit

Notes